Wednesday, June 1, 2016

BRIEF-Kite Pharma granted priority medicines regulatory support access for KTE-C19

* Kite Pharma granted priority medicines regulatory support

access for KTE-C19 in treatment of chemorefractory diffuse large

b-cell lymphoma

Source text for Eikon:

Further company coverage:

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)